Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.
Tashjian
Armen H
AH
Department of Cancer Cell Biology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Chabner
Bruce A
BA
D000818:Animals; D001681:Biological Assay; D003257:Consumer Product Safety; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011994:Recombinant Proteins